Printer Friendly

INSPECTION OF CORDIS' NEUROSCIENCE PRODUCTION FACILITY SUCCESSFULLY CONCLUDED

 INSPECTION OF CORDIS' NEUROSCIENCE PRODUCTION
 FACILITY SUCCESSFULLY CONCLUDED
 MIAMI, July 27 /PRNewswire/ -- Cordis Corporation (NASDAQ-NMS: CORD) said today that its Biot, France, neuroscience production facility has successfully completed a three-day U.S. Food and Drug Administration inspection initiated July 20.
 The outcome should clear the way for the lifting of an important ban into the U.S. of all devices manufactured at that facility. The company indicated that while such action may take place within several weeks, the actual timing is dependent upon FDA.
 Announced by the company May 11, the ban was the result of observations noted during a routine plant inspection conducted in January 1992. Cordis immediately implemented corrective actions at the facility and submitted the changes to FDA. The agency's latest inspection confirmed implementation of those actions.
 Miami-based Cordis Corporation manufactures and markets a variety of medical devices and systems for the angiographic and neuroscience markets. Shares of the company's stock are traded on the NASDAQ National Market under the symbol CORD.
 -0- 7/27/92
 /CONTACT: Chick McDowell, vice president of corporate relations and assistant secretary of Cordis Corporation, 305-824-2821/
 (CORD) CO: Cordis Corporation ST: Florida IN: MTC SU:


AW-JB -- FL003 -- 3359 07/27/92 09:02 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 27, 1992
Words:202
Previous Article:WEITEK, SIERRA SEMICONDUCTOR TO JOINTLY DEVELOP FAMILY OF SINGLE-CHIP, TRUE COLOR USER INTERFACE CONTROLLERS
Next Article:DOW CORNING CORPORATION SECOND-QUARTER FINANCIAL RESULTS REPORTED
Topics:


Related Articles
CORDIS REPORTS IMPROVED SECOND-QUARTER SALES AND EARNINGS
CORDIS SAYS FDA RULES AGAINST ADDITIONAL INFORMATION
CORDIS REPORTS SEC FILINGS
CORDIS REPORTS RECORD FISCAL 1992 RESULTS
CORDIS REPORTS SHARPLY HIGHER FIRST QUARTER RESULTS
CORDIS' SECOND QUARTER EARNINGS UP 24 PERCENT
CORDIS ANNOUNCES STOCK REPURCHASE PROGRAM
CORDIS' SLEEK CATHETER RECEIVES "APPROVABLE LETTER"
CORDIS' THIRD QUARTER NET INCOME UP 19 PERCENT
FOUR CORDIS ANGIOPLASTY CATHETERS APPROVED FOR US MARKET RELEASE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters